Neoadjuvant Tislelizumab, Gemcitabine, Cisplatin and S-1 for Patients with Resectable High-risk Intrahepatic Cholangiocarcinoma
Latest Information Update: 11 Apr 2025
At a glance
- Drugs Cisplatin (Primary) ; Gemcitabine (Primary) ; Gimeracil/oteracil/tegafur (Primary) ; Tislelizumab (Primary)
- Indications Cholangiocarcinoma
- Focus Therapeutic Use
- 11 Apr 2025 New trial record